Actively Recruiting

All Genders
NCT05871762

Choice of the Optimal Treatment Strategies for Mid-low REctal Cancer

Led by Peking Union Medical College Hospital · Updated on 2023-08-28

3705

Participants Needed

1

Research Sites

206 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to compare the efficacy, prognosis, health economics of different treatment modalities of mid-low rectal cancer in different centers in China, and to conduct cost utility analysis (CUA) on the treatment process of rectal cancer to explore the best treatment modality that meets the actual need of medical units in each region and at each level. The investigators hope to provide evidence-based medical suggestions for medical quality control of rectal cancer and revision of clinical guidelines, and provides a source of decision making for medical management and medical insurance.

CONDITIONS

Official Title

Choice of the Optimal Treatment Strategies for Mid-low REctal Cancer

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Pathologically confirmed rectal adenocarcinoma
  • Tumor located within 12 centimeters below the anal verge
Not Eligible

You will not qualify if you...

  • Diagnosed with distant metastasis
  • Multiple primary colorectal cancers
  • History of previous malignant tumors
  • Pregnant or lactating women

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China, 100730

Actively Recruiting

Loading map...

Research Team

Y

Yi Xiao, Professor

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here